| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Emanuela Mazzon | Q56849438 |
| Giuseppe Tardiolo | Q90515081 | ||
| P2093 | author name string | Placido Bramanti | |
| P2860 | cites work | The New Cholinesterase Inhibitors for Alzheimer's Disease, Part 2: Illustrating Their Mechanisms of Action | Q22241109 |
| The importance of neuritic plaques and tangles to the development and evolution of AD | Q22241659 | ||
| Gabapentin for chronic neuropathic pain and fibromyalgia in adults | Q24194998 | ||
| Phosphorylation of parkin by Parkinson disease-linked kinase PINK1 activates parkin E3 ligase function and NF-kappaB signaling | Q24313304 | ||
| N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities | Q24568289 | ||
| Recommendations for the pharmacological management of neuropathic pain: an overview and literature update | Q24616897 | ||
| The influence of N-acetyl-L-cystein infusion on cytokine levels and gastric intramucosal pH during severe sepsis | Q24800533 | ||
| The glutamate receptor ion channels | Q28137916 | ||
| The systemic availability of oral glutathione | Q28184603 | ||
| Distinct nuclear factor-kappaB/Rel proteins have opposing modulatory effects in glutamate-induced cell death in HT22 cells | Q28192145 | ||
| Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death | Q28217736 | ||
| Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients | Q28257370 | ||
| The promise of N-acetylcysteine in neuropsychiatry | Q28284644 | ||
| In vitro studies of amyloid beta-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692-->Gly) Alzheimer's disease | Q28363291 | ||
| Mitochondria and apoptosis | Q29547905 | ||
| Pharmacology and functions of metabotropic glutamate receptors | Q29619150 | ||
| Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders | Q29619537 | ||
| N-Acetyl Cysteine May Support Dopamine Neurons in Parkinson's Disease: Preliminary Clinical and Cell Line Data | Q30000089 | ||
| N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? | Q30474021 | ||
| Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct | Q31029246 | ||
| Administration of N-acetylcysteine after focal cerebral ischemia protects brain and reduces inflammation in a rat model of experimental stroke | Q44870573 | ||
| Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO-mediated pathway not involving peroxynitrite: implications for Parkinson's disease | Q45269246 | ||
| Tissue-specific changes of mitochondrial functions in aged rats: effect of a long-term dietary treatment with N-acetylcysteine | Q45275305 | ||
| Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice | Q46232854 | ||
| Different protection of K252a and N-acetyl-L-cysteine against amyloid-beta peptide-induced cortical neuron apoptosis involving inhibition of MLK3-MKK7-JNK3 signal cascades | Q46296648 | ||
| Quinone and oxyradical scavenging properties of N-acetylcysteine prevent dopamine mediated inhibition of Na+, K+-ATPase and mitochondrial electron transport chain activity in rat brain: implications in the neuroprotective therapy of Parkinson's dise | Q46527836 | ||
| N-acetylcysteine prevents beta-amyloid toxicity by a stimulatory effect on p35/cyclin-dependent kinase 5 activity in cultured cortical neurons | Q46567564 | ||
| Role of oxidative stress in pathophysiology of peripheral neuropathy and modulation by N-acetyl-L-cysteine in rats | Q46743652 | ||
| The effect of ethyl pyruvate and N-acetylcysteine on ischemia-reperfusion injury in an experimental model of ischemic stroke | Q47818081 | ||
| Genetic and environmental risk factors in Parkinson's disease | Q47938136 | ||
| Evaluation of the Neuroprotective Potential of N-Acetylcysteine for Prevention and Treatment of Cognitive Aging and Dementia | Q47946531 | ||
| N-acetylcysteine elicited increase in cytochrome c oxidase activity in mice synaptic mitochondria. | Q48087819 | ||
| Repeated-Dose Oral N-Acetylcysteine in Parkinson's Disease: Pharmacokinetics and Effect on Brain Glutathione and Oxidative Stress | Q48100438 | ||
| In vivo modulation of rodent glutathione and its role in peroxynitrite-induced neocortical synaptosomal membrane protein damage | Q48249285 | ||
| Ultrastructural characteristics of tau filaments in tauopathies: immuno-electron microscopic demonstration of tau filaments in tauopathies | Q48380434 | ||
| Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model | Q48381823 | ||
| Antioxidants attenuate multiple phases of formalin-induced nociceptive response in mice. | Q48443158 | ||
| Protective effect of N-acetyl-L-cysteine on amyloid beta-peptide-induced learning and memory deficits in mice | Q48461244 | ||
| Aggregated amyloid-beta protein induces cortical neuronal apoptosis and concomitant "apoptotic" pattern of gene induction. | Q48620994 | ||
| Oxidized glutathione modulates N-methyl-D-aspartate- and depolarization-induced increases in intracellular Ca2+ in cultured rat forebrain neurons | Q48622602 | ||
| N-acetylcysteine protects against age-related increase in oxidized proteins in mouse synaptic mitochondria | Q48658513 | ||
| Normobaric Hyperoxia Extends Neuro- and Vaso-Protection of N-Acetylcysteine in Transient Focal Ischemia | Q48737963 | ||
| Limb remote postconditioning alleviates cerebral reperfusion injury through reactive oxygen species-mediated inhibition of delta protein kinase C in rats | Q48933902 | ||
| Age-related increase in oxidized proteins in mouse synaptic mitochondria | Q48939604 | ||
| N-acetylcysteine treatment attenuates the cognitive impairment and synaptic plasticity loss induced by streptozotocin. | Q50438231 | ||
| Maintenance of Cognitive Performance and Mood for Individuals with Alzheimer's Disease Following Consumption of a Nutraceutical Formulation: A One-Year, Open-Label Study. | Q50663391 | ||
| A Phase II Randomized Clinical Trial of a Nutritional Formulation for Cognition and Mood in Alzheimer's Disease. | Q50758347 | ||
| Reactive oxygen species enhance excitatory synaptic transmission in rat spinal dorsal horn neurons by activating TRPA1 and TRPV1 channels. | Q50960514 | ||
| N-acetyl-cysteine attenuates neuropathic pain by suppressing matrix metalloproteinases. | Q51532696 | ||
| N-Acetylcysteine delays age-associated memory impairment in mice: role in synaptic mitochondria. | Q52029587 | ||
| Diabetes enhances oxidative stress-induced TRPM2 channel activity and its control by N-acetylcysteine in rat dorsal root ganglion and brain. | Q52145830 | ||
| Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. | Q53248798 | ||
| N-Acetylcysteine for the Treatment of Psychiatric Disorders: A Review of Current Evidence | Q58698161 | ||
| Neuropathic pain | Q59510177 | ||
| N -Acetylcysteine Enhances Hippocampal Neuronal Survival After Transient Forebrain Ischemia in Rats | Q60153477 | ||
| Effect of N-acetylcysteine on the spinal-cord glutathione system and nitric-oxide metabolites in rats with neuropathic pain | Q61182724 | ||
| N-acetylcysteine elicited increase in complex I activity in synaptic mitochondria from aged mice: implications for treatment of Parkinson's disease | Q64787845 | ||
| Regulation of gamma-glutamyl-cysteine synthetase by nonallosteric feedback inhibition by glutathione | Q66909758 | ||
| Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. | Q67228281 | ||
| Dose dependent pharmacokinetics of N-acetylcysteine after oral dosing to man | Q68758976 | ||
| Metabolism of N-acetyl-L-cysteine. Some structural requirements for the deacetylation and consequences for the oral bioavailability | Q69403184 | ||
| Immunomodulatory and protective effects of N-acetylcysteine in mitogen-activated murine splenocytes in vitro | Q73040013 | ||
| In-vivo glutathione elevation protects against hydroxyl free radical-induced protein oxidation in rat brain | Q73453586 | ||
| N-acetylcysteine suppresses TNF-induced NF-kappaB activation through inhibition of IkappaB kinases | Q73731634 | ||
| N-acetyl cysteine inhibits induction of no production by endotoxin or cytokine stimulated rat peritoneal macrophages, C6 glial cells and astrocytes | Q74069333 | ||
| Prevention of PC12 cell death by N-acetylcysteine requires activation of the Ras pathway | Q74562743 | ||
| Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein | Q74736370 | ||
| Parkinsonism in Ontario: increased mortality compared with controls in a large cohort study | Q77387951 | ||
| Sulfasalazine attenuates ACL transection and medial menisectomy-induced cartilage destruction by inhibition of cystine/glutamate antiporter | Q86487669 | ||
| Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis | Q33215518 | ||
| Hypothesis: can N-acetylcysteine be beneficial in Parkinson's disease? | Q33607640 | ||
| Oral N-Acetyl-Cysteine Attenuates Loss of Dopaminergic Terminals in α-Synuclein Overexpressing Mice | Q33680232 | ||
| Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease | Q33915362 | ||
| The origin and neuronal function of in vivo nonsynaptic glutamate. | Q34155228 | ||
| Stroke intervention pathways: NMDA receptors and beyond | Q34163807 | ||
| System xc⁻ cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. | Q34184493 | ||
| The chemistry and biological activities of N-acetylcysteine | Q34341263 | ||
| Glutathione is an endogenous ligand of rat brain N-methyl-D-aspartate (NMDA) and 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors | Q34434863 | ||
| Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia | Q34473140 | ||
| Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review | Q34475761 | ||
| Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking | Q34480486 | ||
| N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects. | Q34543171 | ||
| Role of membrane transport in metabolism and function of glutathione in mammals | Q34558675 | ||
| NMDA receptor subunits: function and pharmacology. | Q34579640 | ||
| From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment | Q34632695 | ||
| Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress | Q34657995 | ||
| Pharmacologic management of neuropathic pain: evidence-based recommendations | Q34699259 | ||
| Metabotropic glutamate receptor involvement in models of acute and persistent pain: prospects for the development of novel analgesics | Q35137409 | ||
| Role of distinct NMDA receptor subtypes at central synapses | Q35923174 | ||
| Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents. | Q35950157 | ||
| The role of glutathione in radiation and drug induced cytotoxicity. | Q36290861 | ||
| Tumor necrosis factor alpha-induced apoptosis in human neuronal cells: protection by the antioxidant N-acetylcysteine and the genes bcl-2 and crmA | Q36550693 | ||
| Oxidative damage in mild cognitive impairment and early Alzheimer's disease | Q36825753 | ||
| Mitochondrial dysfunction in aging and Alzheimer's disease: strategies to protect neurons | Q36909218 | ||
| N-acetylcysteine and neurodegenerative diseases: basic and clinical pharmacology | Q36939735 | ||
| Acetylcholine esterase activity in mild cognitive impairment and Alzheimer's disease | Q37057317 | ||
| Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders | Q37167095 | ||
| Lipopolysaccharide-induced peroxisomal dysfunction exacerbates cerebral white matter injury: attenuation by N-acetyl cysteine | Q37170694 | ||
| Molecular mechanisms of L-DOPA-induced dyskinesia | Q37247578 | ||
| Metabotropic receptors for glutamate and GABA in pain. | Q37369271 | ||
| Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine | Q37533087 | ||
| The glutamate homeostasis hypothesis of addiction | Q37538517 | ||
| ??? | Q64767196 | ||
| Activated astroglia during chronic inflammation in Alzheimer's disease--do they neglect their neurosupportive roles? | Q37596067 | ||
| N-Acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases. | Q37603362 | ||
| Hypoxia-inducible factor 1 contributes to N-acetylcysteine's protection in stroke | Q37619972 | ||
| The functional neurophysiology of the amyloid precursor protein (APP) processing pathway | Q37694798 | ||
| Clinical pharmacokinetics of N-acetylcysteine | Q37713718 | ||
| Antioxidant approaches for the treatment of Alzheimer's disease | Q37768449 | ||
| Molecular basis of NMDA receptor functional diversity. | Q37852112 | ||
| Glutamatergic medications for the treatment of drug and behavioral addictions | Q37871133 | ||
| Nutritional approaches to modulate oxidative stress in Alzheimer's disease | Q37878523 | ||
| Molecular mechanisms of l-DOPA-induced dyskinesia. | Q37930022 | ||
| What Future Role Might N-Acetyl-Cysteine Have in the Treatment of Obsessive Compulsive and Grooming Disorders?: A Systematic Review. | Q38656700 | ||
| 2016 Alzheimer's disease facts and figures | Q39444315 | ||
| Role of glutathione and other endogenous thiols in radiation protection | Q39546805 | ||
| Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease | Q40352054 | ||
| 1 Glutathione metabolism | Q40468949 | ||
| The protection conferred against ischemia-reperfusion injury in the diabetic brain by N-acetylcysteine is associated with decreased dicarbonyl stress | Q40797864 | ||
| Are dopaminergic neurons selectively vulnerable to Parkinson's disease? | Q40868945 | ||
| Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease. | Q41740537 | ||
| N-Acetyl-cysteine causes analgesia by reinforcing the endogenous activation of type-2 metabotropic glutamate receptors. | Q41843975 | ||
| Determining the critical nucleus and mechanism of fibril elongation of the Alzheimer's Abeta(1-40) peptide. | Q42059881 | ||
| N-acetylcysteine downregulates phosphorylated p-38 expression but does not reverse the increased superoxide anion levels in the spinal cord of rats with neuropathic pain | Q42317396 | ||
| Reduced intravenous glutathione in the treatment of early Parkinson's disease | Q42644977 | ||
| Effects of N-acetylcysteine on spinal cord oxidative stress biomarkers in rats with neuropathic pain | Q42664517 | ||
| Maintenance of glutathione content is isolated hepatocyctes | Q42932952 | ||
| Potential in vivo amelioration by N-acetyl-L-cysteine of oxidative stress in brain in human double mutant APP/PS-1 knock-in mice: toward therapeutic modulation of mild cognitive impairment | Q42963006 | ||
| Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases | Q43130235 | ||
| Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study | Q43147200 | ||
| Integrated regulation of signal coding and plasticity by NMDA receptors at a central synapse. | Q43182255 | ||
| Transcriptional regulation of type-2 metabotropic glutamate receptors: an epigenetic path to novel treatments for chronic pain | Q43197524 | ||
| Pyruvate released by astrocytes protects neurons from copper-catalyzed cysteine neurotoxicity. | Q43594208 | ||
| Therapeutic potential of N-acetylcysteine in age-related mitochondrial neurodegenerative diseases | Q43599271 | ||
| Glutathione elevation and its protective role in acrolein-induced protein damage in synaptosomal membranes: relevance to brain lipid peroxidation in neurodegenerative disease | Q43641383 | ||
| The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. | Q43681037 | ||
| Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model. | Q43787467 | ||
| N-Acetyl-L-Cystein downregulates beta-amyloid precursor protein gene transcription in human neuroblastoma cells | Q43799400 | ||
| N-acetyl-L-cysteine inhibits 26S proteasome function: implications for effects on NF-kappaB activation | Q43962734 | ||
| 3-nitropropionic acid-induced changes in bilayer fluidity in synaptosomal membranes: implications for Huntington's disease | Q44116936 | ||
| Antioxidants inhibit the human cortical neuron apoptosis induced by hydrogen peroxide, tumor necrosis factor alpha, dopamine and beta-amyloid peptide 1-42. | Q44319953 | ||
| The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice | Q44326540 | ||
| N-Acetyl cysteine protects against injury in a rat model of focal cerebral ischemia | Q44401022 | ||
| Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse | Q44460612 | ||
| Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease. | Q44591949 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | amino acid | Q8066 |
| neurodegeneration | Q1755122 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 3305 | |
| P577 | publication date | 2018-12-13 | |
| P1433 | published in | Molecules | Q151332 |
| P1476 | title | Overview on the Effects of N-Acetylcysteine in Neurodegenerative Diseases | |
| P478 | volume | 23 |
| Q90385275 | Antinociceptive and anti-inflammatory effects of N-acetylcysteine and verapamil in Wistar rats |
| Q90522821 | Antioxidants Reduce Muscular Dystrophy in the dy2J/dy2J Mouse Model of Laminin α2 Chain-Deficient Muscular Dystrophy |
| Q89599040 | Exposure of CuO Nanoparticles Contributes to Cellular Apoptosis, Redox Stress, and Alzheimer's Aβ Amyloidosis |
| Q91611173 | Medical and Dietary Uses of N-Acetylcysteine |
| Q92167765 | Oxidative stress-induced angiogenesis is mediated by miR-205-5p |
| Q91738703 | Protective potentials of Annona muricata fruit pulp on etoposide-induced gastrointestinal toxicity in Wistar rats |
| Q98224443 | Spotlight on Ferroptosis: Iron-Dependent Cell Death in Alzheimer's Disease |
| Q64891767 | The Role of N-Methyl-D-Aspartate Receptor Neurotransmission and Precision Medicine in Behavioral and Psychological Symptoms of Dementia. |
Search more.